Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Growth 2026-2032
The global Non-steroidal Androgen Receptor Inhibitors?NSARIs? market size is predicted to grow from US$ 4738 million in 2025 to US$ 18506 million in 2032; it is expected to grow at a CAGR of 21.6% from 2026 to 2032.
Non-steroidal androgen receptor inhibitors (NSARIs) are a class of oral small-molecule drugs that competitively bind to the androgen receptor (AR), inhibiting its nuclear translocation and transcriptional activity without possessing a steroidal structure; they selectively block androgen signaling pathways that drive prostate cancer progression and represent a core component of endocrine therapy for prostate cancer; the class has evolved from first-generation agents (e.g., bicalutamide) to second-generation high-affinity inhibitors such as Enzalutamide, Apalutamide, and Darolutamide, with continuous improvements in efficacy, resistance management, and safety profile, primarily indicated for nmCRPC and mHSPC and typically used in combination with androgen deprivation therapy (ADT).The global market for non-steroidal androgen receptor inhibitors is estimated at USD 4.8 billion in 2025, with a projected CAGR of approximately 20.85% from 2025 to 2030, corresponding to an annual treated patient population of about 500,000?600,000, driven by increasing penetration in nmCRPC, mCRPC, and mHSPC. Nominal capacity from the global high-potency small-molecule API network is sufficient to meet demand, and capacity does not constitute a constraint. Average treatment cost per patient per year is approximately USD 90,000?100,000 in the U.S., USD 50,000?70,000 in Europe, and USD 15,000?20,000 in China post-reimbursement negotiations, resulting in a weighted average of about USD 65,000 per patient per year, with a blended gross margin of roughly 85?90%.
Downstream demand is concentrated in the prostate cancer treatment pathway within oncology (nmCRPC ? mCRPC ? mHSPC). The value chain upstream consists of high-potency APIs and key intermediates synthesized via multi-step heterocyclic processes; midstream commercialization is led by originator companies (Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson, and Bayer AG/Orion Corporation); downstream channels consist of hospitals and oncology specialty clinics. The global industry structure is characterized by ?originator oligopoly + guideline-driven adoption + patent protection,? with primary competition from Enzalutamide, Apalutamide, and Darolutamide. The core compound patent of Darolutamide is expected to expire around 2030, but indication, formulation, and regional patent extensions may prolong actual market exclusivity to 2032?2035. Overall, the market is in the late growth stage, driven primarily by indication expansion and an increasing aging patient population, with key uncertainty arising from post-patent generic entry and reimbursement pressure.
LP Information, Inc. (LPI) ' newest research report, the ?Non-steroidal Androgen Receptor Inhibitors?NSARIs? Industry Forecast? looks at past sales and reviews total world Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales in 2025, providing a comprehensive analysis by region and market sector of projected Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales for 2026 through 2032. With Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-steroidal Androgen Receptor Inhibitors?NSARIs? industry.
This Insight Report provides a comprehensive analysis of the global Non-steroidal Androgen Receptor Inhibitors?NSARIs? landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-steroidal Androgen Receptor Inhibitors?NSARIs? portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Non-steroidal Androgen Receptor Inhibitors?NSARIs? market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-steroidal Androgen Receptor Inhibitors?NSARIs? and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-steroidal Androgen Receptor Inhibitors?NSARIs?.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-steroidal Androgen Receptor Inhibitors?NSARIs? market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Non-steroidal Androgen Receptor Inhibitors?NSARIs? market?
What factors are driving Non-steroidal Androgen Receptor Inhibitors?NSARIs? market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-steroidal Androgen Receptor Inhibitors?NSARIs? market opportunities vary by end market size?
How does Non-steroidal Androgen Receptor Inhibitors?NSARIs? break out by Type, by Application?
Non-steroidal androgen receptor inhibitors (NSARIs) are a class of oral small-molecule drugs that competitively bind to the androgen receptor (AR), inhibiting its nuclear translocation and transcriptional activity without possessing a steroidal structure; they selectively block androgen signaling pathways that drive prostate cancer progression and represent a core component of endocrine therapy for prostate cancer; the class has evolved from first-generation agents (e.g., bicalutamide) to second-generation high-affinity inhibitors such as Enzalutamide, Apalutamide, and Darolutamide, with continuous improvements in efficacy, resistance management, and safety profile, primarily indicated for nmCRPC and mHSPC and typically used in combination with androgen deprivation therapy (ADT).The global market for non-steroidal androgen receptor inhibitors is estimated at USD 4.8 billion in 2025, with a projected CAGR of approximately 20.85% from 2025 to 2030, corresponding to an annual treated patient population of about 500,000?600,000, driven by increasing penetration in nmCRPC, mCRPC, and mHSPC. Nominal capacity from the global high-potency small-molecule API network is sufficient to meet demand, and capacity does not constitute a constraint. Average treatment cost per patient per year is approximately USD 90,000?100,000 in the U.S., USD 50,000?70,000 in Europe, and USD 15,000?20,000 in China post-reimbursement negotiations, resulting in a weighted average of about USD 65,000 per patient per year, with a blended gross margin of roughly 85?90%.
Downstream demand is concentrated in the prostate cancer treatment pathway within oncology (nmCRPC ? mCRPC ? mHSPC). The value chain upstream consists of high-potency APIs and key intermediates synthesized via multi-step heterocyclic processes; midstream commercialization is led by originator companies (Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson, and Bayer AG/Orion Corporation); downstream channels consist of hospitals and oncology specialty clinics. The global industry structure is characterized by ?originator oligopoly + guideline-driven adoption + patent protection,? with primary competition from Enzalutamide, Apalutamide, and Darolutamide. The core compound patent of Darolutamide is expected to expire around 2030, but indication, formulation, and regional patent extensions may prolong actual market exclusivity to 2032?2035. Overall, the market is in the late growth stage, driven primarily by indication expansion and an increasing aging patient population, with key uncertainty arising from post-patent generic entry and reimbursement pressure.
LP Information, Inc. (LPI) ' newest research report, the ?Non-steroidal Androgen Receptor Inhibitors?NSARIs? Industry Forecast? looks at past sales and reviews total world Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales in 2025, providing a comprehensive analysis by region and market sector of projected Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales for 2026 through 2032. With Non-steroidal Androgen Receptor Inhibitors?NSARIs? sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-steroidal Androgen Receptor Inhibitors?NSARIs? industry.
This Insight Report provides a comprehensive analysis of the global Non-steroidal Androgen Receptor Inhibitors?NSARIs? landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-steroidal Androgen Receptor Inhibitors?NSARIs? portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Non-steroidal Androgen Receptor Inhibitors?NSARIs? market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-steroidal Androgen Receptor Inhibitors?NSARIs? and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-steroidal Androgen Receptor Inhibitors?NSARIs?.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-steroidal Androgen Receptor Inhibitors?NSARIs? market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Enzalutamide
- Apalutamide
- Darolutamide
- Bicalutamide
- Nilutamide
- High BBB Penetration
- Low BBB Penetration
- nmCRPC
- mCRPC
- mHSPC
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas Pharma
- Pfizer
- Johnson & Johnson
- Bayer AG
- Orion
- Lonza Group
- Catalent
- WuXi AppTec
- Asymchem Laboratories
- Recipharm
What is the 10-year outlook for the global Non-steroidal Androgen Receptor Inhibitors?NSARIs? market?
What factors are driving Non-steroidal Androgen Receptor Inhibitors?NSARIs? market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-steroidal Androgen Receptor Inhibitors?NSARIs? market opportunities vary by end market size?
How does Non-steroidal Androgen Receptor Inhibitors?NSARIs? break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country/Region, 2021, 2025 & 2032
2.2 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Type
2.2.1 Enzalutamide
2.2.2 Apalutamide
2.2.3 Darolutamide
2.2.4 Bicalutamide
2.2.5 Nilutamide
2.2.6 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type
2.2.6.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
2.2.6.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Type (2021-2026)
2.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Molecular
2.3.1 High BBB Penetration
2.3.2 Low BBB Penetration
2.3.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Molecular
2.3.3.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular (2021-2026)
2.3.3.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Molecular (2021-2026)
2.3.3.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Molecular (2021-2026)
2.4 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Application
2.4.1 nmCRPC
2.4.2 mCRPC
2.4.3 mHSPC
2.4.4 Others
2.4.5 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application
2.4.5.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market Share by Application (2021-2026)
2.4.5.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Application (2021-2026)
2.4.5.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Breakdown Data by Company
3.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Company (2021-2026)
3.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Company (2021-2026)
3.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Company (2021-2026)
3.2.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company (2021-2026)
3.2.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Company (2021-2026)
3.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Company
3.4 Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Location Distribution
3.4.2 Players Non-steroidal Androgen Receptor Inhibitors?NSARIs? Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NON-STEROIDAL ANDROGEN RECEPTOR INHIBITORS?NSARIS? BY GEOGRAPHIC REGION
4.1 World Historic Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size by Geographic Region (2021-2026)
4.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size by Country/Region (2021-2026)
4.2.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Country/Region (2021-2026)
4.2.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Country/Region (2021-2026)
4.3 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
4.4 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
4.5 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
4.6 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
5 AMERICAS
5.1 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country
5.1.1 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026)
5.1.2 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026)
5.2 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
5.3 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region
6.1.1 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region (2021-2026)
6.1.2 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Region (2021-2026)
6.2 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
6.3 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country
7.1.1 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026)
7.1.2 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026)
7.2 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
7.3 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country
8.1.1 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026)
8.1.2 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026)
8.2 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
8.3 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
10.3 Manufacturing Process Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
10.4 Industry Chain Structure of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Distributors
11.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Customer
12 WORLD FORECAST REVIEW FOR NON-STEROIDAL ANDROGEN RECEPTOR INHIBITORS?NSARIS? BY GEOGRAPHIC REGION
12.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size Forecast by Region
12.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Region (2027-2032)
12.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Type (2027-2032)
12.7 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma
13.1.1 Astellas Pharma Company Information
13.1.2 Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.1.3 Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Astellas Pharma Main Business Overview
13.1.5 Astellas Pharma Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.2.3 Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Information
13.3.2 Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.3.3 Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Johnson & Johnson Main Business Overview
13.3.5 Johnson & Johnson Latest Developments
13.4 Bayer AG
13.4.1 Bayer AG Company Information
13.4.2 Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.4.3 Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Bayer AG Main Business Overview
13.4.5 Bayer AG Latest Developments
13.5 Orion
13.5.1 Orion Company Information
13.5.2 Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.5.3 Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Orion Main Business Overview
13.5.5 Orion Latest Developments
13.6 Lonza Group
13.6.1 Lonza Group Company Information
13.6.2 Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.6.3 Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Lonza Group Main Business Overview
13.6.5 Lonza Group Latest Developments
13.7 Catalent
13.7.1 Catalent Company Information
13.7.2 Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.7.3 Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Catalent Main Business Overview
13.7.5 Catalent Latest Developments
13.8 WuXi AppTec
13.8.1 WuXi AppTec Company Information
13.8.2 WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.8.3 WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 WuXi AppTec Main Business Overview
13.8.5 WuXi AppTec Latest Developments
13.9 Asymchem Laboratories
13.9.1 Asymchem Laboratories Company Information
13.9.2 Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.9.3 Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Asymchem Laboratories Main Business Overview
13.9.5 Asymchem Laboratories Latest Developments
13.10 Recipharm
13.10.1 Recipharm Company Information
13.10.2 Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.10.3 Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Recipharm Main Business Overview
13.10.5 Recipharm Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country/Region, 2021, 2025 & 2032
2.2 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Type
2.2.1 Enzalutamide
2.2.2 Apalutamide
2.2.3 Darolutamide
2.2.4 Bicalutamide
2.2.5 Nilutamide
2.2.6 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type
2.2.6.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
2.2.6.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Type (2021-2026)
2.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Molecular
2.3.1 High BBB Penetration
2.3.2 Low BBB Penetration
2.3.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Molecular
2.3.3.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular (2021-2026)
2.3.3.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Molecular (2021-2026)
2.3.3.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Molecular (2021-2026)
2.4 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Segment by Application
2.4.1 nmCRPC
2.4.2 mCRPC
2.4.3 mHSPC
2.4.4 Others
2.4.5 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application
2.4.5.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market Share by Application (2021-2026)
2.4.5.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue and Market Share by Application (2021-2026)
2.4.5.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Breakdown Data by Company
3.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Company (2021-2026)
3.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Company (2021-2026)
3.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Company (2021-2026)
3.2.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company (2021-2026)
3.2.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Company (2021-2026)
3.3 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Company
3.4 Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Location Distribution
3.4.2 Players Non-steroidal Androgen Receptor Inhibitors?NSARIs? Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NON-STEROIDAL ANDROGEN RECEPTOR INHIBITORS?NSARIS? BY GEOGRAPHIC REGION
4.1 World Historic Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size by Geographic Region (2021-2026)
4.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size by Country/Region (2021-2026)
4.2.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales by Country/Region (2021-2026)
4.2.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue by Country/Region (2021-2026)
4.3 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
4.4 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
4.5 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
4.6 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth
5 AMERICAS
5.1 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country
5.1.1 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026)
5.1.2 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026)
5.2 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
5.3 Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region
6.1.1 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region (2021-2026)
6.1.2 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Region (2021-2026)
6.2 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
6.3 APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country
7.1.1 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026)
7.1.2 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026)
7.2 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
7.3 Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? by Country
8.1.1 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026)
8.1.2 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026)
8.2 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026)
8.3 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
10.3 Manufacturing Process Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
10.4 Industry Chain Structure of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Distributors
11.3 Non-steroidal Androgen Receptor Inhibitors?NSARIs? Customer
12 WORLD FORECAST REVIEW FOR NON-STEROIDAL ANDROGEN RECEPTOR INHIBITORS?NSARIS? BY GEOGRAPHIC REGION
12.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market Size Forecast by Region
12.1.1 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Region (2027-2032)
12.1.2 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Type (2027-2032)
12.7 Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma
13.1.1 Astellas Pharma Company Information
13.1.2 Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.1.3 Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Astellas Pharma Main Business Overview
13.1.5 Astellas Pharma Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.2.3 Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Information
13.3.2 Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.3.3 Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Johnson & Johnson Main Business Overview
13.3.5 Johnson & Johnson Latest Developments
13.4 Bayer AG
13.4.1 Bayer AG Company Information
13.4.2 Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.4.3 Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Bayer AG Main Business Overview
13.4.5 Bayer AG Latest Developments
13.5 Orion
13.5.1 Orion Company Information
13.5.2 Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.5.3 Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Orion Main Business Overview
13.5.5 Orion Latest Developments
13.6 Lonza Group
13.6.1 Lonza Group Company Information
13.6.2 Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.6.3 Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Lonza Group Main Business Overview
13.6.5 Lonza Group Latest Developments
13.7 Catalent
13.7.1 Catalent Company Information
13.7.2 Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.7.3 Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Catalent Main Business Overview
13.7.5 Catalent Latest Developments
13.8 WuXi AppTec
13.8.1 WuXi AppTec Company Information
13.8.2 WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.8.3 WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 WuXi AppTec Main Business Overview
13.8.5 WuXi AppTec Latest Developments
13.9 Asymchem Laboratories
13.9.1 Asymchem Laboratories Company Information
13.9.2 Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.9.3 Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Asymchem Laboratories Main Business Overview
13.9.5 Asymchem Laboratories Latest Developments
13.10 Recipharm
13.10.1 Recipharm Company Information
13.10.2 Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
13.10.3 Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Recipharm Main Business Overview
13.10.5 Recipharm Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Enzalutamide
Table 4. Major Players of Apalutamide
Table 5. Major Players of Darolutamide
Table 6. Major Players of Bicalutamide
Table 7. Major Players of Nilutamide
Table 8. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 9. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Table 10. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Type (2021-2026) & ($ million)
Table 11. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Type (2021-2026)
Table 12. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Type (2021-2026) & (US$/Ton)
Table 13. Major Players of High BBB Penetration
Table 14. Major Players of Low BBB Penetration
Table 15. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Molecular (2021-2026) & (Tons)
Table 16. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular (2021-2026)
Table 17. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Molecular (2021-2026) & ($ million)
Table 18. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Molecular (2021-2026)
Table 19. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Molecular (2021-2026) & (US$/Ton)
Table 20. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale by Application (2021-2026) & (Tons)
Table 21. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market Share by Application (2021-2026)
Table 22. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Application (2021-2026) & ($ million)
Table 23. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Application (2021-2026)
Table 24. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Application (2021-2026) & (US$/Ton)
Table 25. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Company (2021-2026) & (Tons)
Table 26. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Company (2021-2026)
Table 27. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company (2021-2026) & ($ millions)
Table 28. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Company (2021-2026)
Table 29. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Company (2021-2026) & (US$/Ton)
Table 30. Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Producing Area Distribution and Sales Area
Table 31. Players Non-steroidal Androgen Receptor Inhibitors?NSARIs? Products Offered
Table 32. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 33. New Products and Potential Entrants
Table 34. Market M&A Activity & Strategy
Table 35. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Geographic Region (2021-2026) & (Tons)
Table 36. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Geographic Region (2021-2026)
Table 37. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Geographic Region (2021-2026) & ($ millions)
Table 38. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Geographic Region (2021-2026)
Table 39. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country/Region (2021-2026) & (Tons)
Table 40. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2021-2026)
Table 41. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country/Region (2021-2026) & ($ millions)
Table 42. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country/Region (2021-2026)
Table 43. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)
Table 44. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country (2021-2026)
Table 45. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026) & ($ millions)
Table 46. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 47. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)
Table 48. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region (2021-2026) & (Tons)
Table 49. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Region (2021-2026)
Table 50. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Region (2021-2026) & ($ millions)
Table 51. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 52. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)
Table 53. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)
Table 54. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026) & ($ millions)
Table 55. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 56. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)
Table 57. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)
Table 58. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)
Table 59. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 60. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)
Table 61. Key Market Drivers & Growth Opportunities of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Table 62. Key Market Challenges & Risks of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Table 63. Key Industry Trends of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Table 64. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Distributors List
Table 67. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Customer List
Table 68. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Region (2027-2032) & (Tons)
Table 69. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)
Table 71. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Region (2027-2032) & (Tons)
Table 73. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)
Table 75. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)
Table 77. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Type (2027-2032) & (Tons)
Table 79. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Type (2027-2032) & ($ millions)
Table 80. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Application (2027-2032) & (Tons)
Table 81. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Application (2027-2032) & ($ millions)
Table 82. Astellas Pharma Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 83. Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 84. Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 85. Astellas Pharma Main Business
Table 86. Astellas Pharma Latest Developments
Table 87. Pfizer Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 89. Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 90. Pfizer Main Business
Table 91. Pfizer Latest Developments
Table 92. Johnson & Johnson Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 93. Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 94. Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 95. Johnson & Johnson Main Business
Table 96. Johnson & Johnson Latest Developments
Table 97. Bayer AG Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 98. Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 99. Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 100. Bayer AG Main Business
Table 101. Bayer AG Latest Developments
Table 102. Orion Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 103. Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 104. Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 105. Orion Main Business
Table 106. Orion Latest Developments
Table 107. Lonza Group Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 108. Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 109. Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 110. Lonza Group Main Business
Table 111. Lonza Group Latest Developments
Table 112. Catalent Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 113. Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 114. Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 115. Catalent Main Business
Table 116. Catalent Latest Developments
Table 117. WuXi AppTec Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 118. WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 119. WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 120. WuXi AppTec Main Business
Table 121. WuXi AppTec Latest Developments
Table 122. Asymchem Laboratories Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 123. Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 124. Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 125. Asymchem Laboratories Main Business
Table 126. Asymchem Laboratories Latest Developments
Table 127. Recipharm Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 128. Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 129. Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 130. Recipharm Main Business
Table 131. Recipharm Latest Developments
Table 1. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Enzalutamide
Table 4. Major Players of Apalutamide
Table 5. Major Players of Darolutamide
Table 6. Major Players of Bicalutamide
Table 7. Major Players of Nilutamide
Table 8. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 9. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Table 10. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Type (2021-2026) & ($ million)
Table 11. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Type (2021-2026)
Table 12. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Type (2021-2026) & (US$/Ton)
Table 13. Major Players of High BBB Penetration
Table 14. Major Players of Low BBB Penetration
Table 15. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Molecular (2021-2026) & (Tons)
Table 16. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular (2021-2026)
Table 17. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Molecular (2021-2026) & ($ million)
Table 18. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Molecular (2021-2026)
Table 19. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Molecular (2021-2026) & (US$/Ton)
Table 20. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale by Application (2021-2026) & (Tons)
Table 21. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market Share by Application (2021-2026)
Table 22. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Application (2021-2026) & ($ million)
Table 23. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Application (2021-2026)
Table 24. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Application (2021-2026) & (US$/Ton)
Table 25. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Company (2021-2026) & (Tons)
Table 26. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Company (2021-2026)
Table 27. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company (2021-2026) & ($ millions)
Table 28. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Company (2021-2026)
Table 29. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Price by Company (2021-2026) & (US$/Ton)
Table 30. Key Manufacturers Non-steroidal Androgen Receptor Inhibitors?NSARIs? Producing Area Distribution and Sales Area
Table 31. Players Non-steroidal Androgen Receptor Inhibitors?NSARIs? Products Offered
Table 32. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 33. New Products and Potential Entrants
Table 34. Market M&A Activity & Strategy
Table 35. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Geographic Region (2021-2026) & (Tons)
Table 36. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Geographic Region (2021-2026)
Table 37. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Geographic Region (2021-2026) & ($ millions)
Table 38. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Geographic Region (2021-2026)
Table 39. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country/Region (2021-2026) & (Tons)
Table 40. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2021-2026)
Table 41. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country/Region (2021-2026) & ($ millions)
Table 42. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country/Region (2021-2026)
Table 43. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)
Table 44. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country (2021-2026)
Table 45. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026) & ($ millions)
Table 46. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 47. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)
Table 48. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Region (2021-2026) & (Tons)
Table 49. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Region (2021-2026)
Table 50. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Region (2021-2026) & ($ millions)
Table 51. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 52. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)
Table 53. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)
Table 54. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Country (2021-2026) & ($ millions)
Table 55. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 56. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)
Table 57. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Country (2021-2026) & (Tons)
Table 58. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)
Table 59. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Type (2021-2026) & (Tons)
Table 60. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Application (2021-2026) & (Tons)
Table 61. Key Market Drivers & Growth Opportunities of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Table 62. Key Market Challenges & Risks of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Table 63. Key Industry Trends of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Table 64. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Distributors List
Table 67. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Customer List
Table 68. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Region (2027-2032) & (Tons)
Table 69. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)
Table 71. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Region (2027-2032) & (Tons)
Table 73. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)
Table 75. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Country (2027-2032) & (Tons)
Table 77. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Type (2027-2032) & (Tons)
Table 79. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Type (2027-2032) & ($ millions)
Table 80. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Forecast by Application (2027-2032) & (Tons)
Table 81. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Forecast by Application (2027-2032) & ($ millions)
Table 82. Astellas Pharma Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 83. Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 84. Astellas Pharma Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 85. Astellas Pharma Main Business
Table 86. Astellas Pharma Latest Developments
Table 87. Pfizer Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 89. Pfizer Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 90. Pfizer Main Business
Table 91. Pfizer Latest Developments
Table 92. Johnson & Johnson Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 93. Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 94. Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 95. Johnson & Johnson Main Business
Table 96. Johnson & Johnson Latest Developments
Table 97. Bayer AG Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 98. Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 99. Bayer AG Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 100. Bayer AG Main Business
Table 101. Bayer AG Latest Developments
Table 102. Orion Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 103. Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 104. Orion Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 105. Orion Main Business
Table 106. Orion Latest Developments
Table 107. Lonza Group Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 108. Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 109. Lonza Group Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 110. Lonza Group Main Business
Table 111. Lonza Group Latest Developments
Table 112. Catalent Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 113. Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 114. Catalent Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 115. Catalent Main Business
Table 116. Catalent Latest Developments
Table 117. WuXi AppTec Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 118. WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 119. WuXi AppTec Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 120. WuXi AppTec Main Business
Table 121. WuXi AppTec Latest Developments
Table 122. Asymchem Laboratories Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 123. Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 124. Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 125. Asymchem Laboratories Main Business
Table 126. Asymchem Laboratories Latest Developments
Table 127. Recipharm Basic Information, Non-steroidal Androgen Receptor Inhibitors?NSARIs? Manufacturing Base, Sales Area and Its Competitors
Table 128. Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Product Portfolios and Specifications
Table 129. Recipharm Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 130. Recipharm Main Business
Table 131. Recipharm Latest Developments
LIST OF FIGURES
Figure 1. Picture of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Figure 2. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth Rate 2021-2032 (Tons)
Figure 7. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2025)
Figure 10. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Enzalutamide
Figure 12. Product Picture of Apalutamide
Figure 13. Product Picture of Darolutamide
Figure 14. Product Picture of Bicalutamide
Figure 15. Product Picture of Nilutamide
Figure 16. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type in 2026
Figure 17. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of High BBB Penetration
Figure 19. Product Picture of Low BBB Penetration
Figure 20. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular in 2026
Figure 21. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Molecular (2021-2026)
Figure 22. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in nmCRPC
Figure 23. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: nmCRPC (2021-2026) & (Tons)
Figure 24. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in mCRPC
Figure 25. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: mCRPC (2021-2026) & (Tons)
Figure 26. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in mHSPC
Figure 27. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: mHSPC (2021-2026) & (Tons)
Figure 28. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in Others
Figure 29. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: Others (2021-2026) & (Tons)
Figure 30. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market Share by Application (2025)
Figure 31. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Application in 2025
Figure 32. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Company in 2025 (Tons)
Figure 33. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Company in 2025
Figure 34. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company in 2025 ($ millions)
Figure 35. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Company in 2025
Figure 36. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales 2021-2026 (Tons)
Figure 39. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 ($ millions)
Figure 40. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales 2021-2026 (Tons)
Figure 41. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 ($ millions)
Figure 42. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales 2021-2026 (Tons)
Figure 43. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales 2021-2026 (Tons)
Figure 45. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 ($ millions)
Figure 46. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country in 2025
Figure 47. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)
Figure 48. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Figure 49. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)
Figure 50. United States Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Region in 2025
Figure 55. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Region (2021-2026)
Figure 56. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Figure 57. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)
Figure 58. China Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 62. India Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country in 2025
Figure 66. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)
Figure 67. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Figure 68. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)
Figure 69. Germany Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 70. France Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)
Figure 77. Egypt Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs? in 2026
Figure 83. Manufacturing Process Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Figure 84. Industry Chain Structure of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Figure 85. Channels of Distribution
Figure 86. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Forecast by Region (2027-2032)
Figure 87. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Figure 2. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Growth Rate 2021-2032 (Tons)
Figure 7. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2025)
Figure 10. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Enzalutamide
Figure 12. Product Picture of Apalutamide
Figure 13. Product Picture of Darolutamide
Figure 14. Product Picture of Bicalutamide
Figure 15. Product Picture of Nilutamide
Figure 16. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type in 2026
Figure 17. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of High BBB Penetration
Figure 19. Product Picture of Low BBB Penetration
Figure 20. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Molecular in 2026
Figure 21. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Molecular (2021-2026)
Figure 22. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in nmCRPC
Figure 23. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: nmCRPC (2021-2026) & (Tons)
Figure 24. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in mCRPC
Figure 25. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: mCRPC (2021-2026) & (Tons)
Figure 26. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in mHSPC
Figure 27. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: mHSPC (2021-2026) & (Tons)
Figure 28. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Consumed in Others
Figure 29. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Market: Others (2021-2026) & (Tons)
Figure 30. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sale Market Share by Application (2025)
Figure 31. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Application in 2025
Figure 32. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales by Company in 2025 (Tons)
Figure 33. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Company in 2025
Figure 34. Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue by Company in 2025 ($ millions)
Figure 35. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Company in 2025
Figure 36. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales 2021-2026 (Tons)
Figure 39. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 ($ millions)
Figure 40. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales 2021-2026 (Tons)
Figure 41. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 ($ millions)
Figure 42. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales 2021-2026 (Tons)
Figure 43. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales 2021-2026 (Tons)
Figure 45. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue 2021-2026 ($ millions)
Figure 46. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country in 2025
Figure 47. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)
Figure 48. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Figure 49. Americas Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)
Figure 50. United States Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Region in 2025
Figure 55. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Region (2021-2026)
Figure 56. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Figure 57. APAC Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)
Figure 58. China Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 62. India Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country in 2025
Figure 66. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share by Country (2021-2026)
Figure 67. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Figure 68. Europe Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)
Figure 69. Germany Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 70. France Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share by Application (2021-2026)
Figure 77. Egypt Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs? in 2026
Figure 83. Manufacturing Process Analysis of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Figure 84. Industry Chain Structure of Non-steroidal Androgen Receptor Inhibitors?NSARIs?
Figure 85. Channels of Distribution
Figure 86. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Forecast by Region (2027-2032)
Figure 87. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Non-steroidal Androgen Receptor Inhibitors?NSARIs? Revenue Market Share Forecast by Application (2027-2032)
